An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients

Arthritis and Rheumatism

Volumn 43, Issue 5, 2000, Pages 1021-1032

  Reinhold Keller, Eva ^a   Beuge, Nadja ^a   Latza, Ute ^a   De Groot, Kirsten ^a   Rudert, Heinrich ^b   Nölle, Bernhard ^b   Heller, Martin ^b   Gross, Wolfgang L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MESNA; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RELAPSE; REMISSION; SURVIVAL TIME; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LONG-TERM CARE; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT CARE TEAM; PREDNISONE; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 0034044534     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J     Document Type: Article

References (37)

1. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener' granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
3. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, et al. Wegener's granulomatosis: a series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. QJM 1992;83: 427-38.
4. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis criteria cohort. Am J Med 1996;101:129-34.
5. Steppat D, Gross WL. Stage-adapted treatment of Wegener's granulomatosis. Klin Wochenschr 1989;67:666-71.
6. Nolle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 1989;111: 28-40.
7. Gross WL. New developments in the treatment of vasculitis. Curr Opin Rheumatol 1994;6:11-9.
8. Gross WL, Rasmussen N. Treatment of Wegener's granulomatosis - the view from two non-nephrologists. Nephrol Dial Transplant 1994;9:1219-25.
9. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
10. Reinhold-Keller E, de Grant K, Rudert H, Nölle B, Heller M, Gross WL. Response to trimethoprim-sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996;89:15-23.
11. De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nölle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996;39:2052-61.
12. De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low-dose methotrexate. J Rheumatol 1998;25:492-5.
13. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
14. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92.
15. Muhle C, Reinhold-Keller E, Richter C, Duncker G, Beigel A, Brinkmann G, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener's granulomatosis. Eur Radiol 1997;7: 566-70.
16. Reuter M, Schnabel A, Wesner F, Tetzlaff K, Risheng Y, Gross WL, et al. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest 1998;114:500-6.
17. DeRemee RA, McDonald TJ, Harrison G, Coles DT. Wegener's granulomatosis: anatomic correlates, a proposed classification. Mayo Clin Proc 1976;51:777-81.
18. De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for ANCA-associated vasculitides. Nephrol Dial Transpl. In press.
19. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
20. Rasmussen N, Jayne DRW, Abramowicz D, Andrassy K, Bacon PA, Cohen Tervaert JW, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995;101: 29-34.
21. Guillevin L, Cordier J-F, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
22. Oscier DG. The myelodysplastic syndromes. BMJ 1997;314:883-6.
23. Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross WL. Treatment of ANCA-associatcd systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
24. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
25. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
26. Shaw IC, Graham MI. Mesna - a short review. Cancer Treat Rev 1987;14:67-86.
27. Jayne DRW, Lockwood CM. Intravenous immunoglobulin as a sole therapy for systemic vasculitis. Br J Rheumatol 1996;35: 1150-3.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Cox DR, Oakes D. Analysis of survival data. New York: Chapman Hall; 1984.
30. Luqmani RA, Bacon PA, Beaman M, Scott DGI, Emery P, Lee SJ, et al. Classical versus non-renal Wegener's granulomatosis. QJM 1994;87:161-7.
31. Romas E, Murphy BF, d'Apice AJF, Kennedy JT, Niall JF. Wegener' granulomatosis: clinical features and prognosis in 37 patients. Aust NZJ Med 1993;23:168-75.
32. Talar-Williams C, Hijazi PYM, Walther MM, Linchan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996;124:477-84.
33. Reinhold-Keller E, Mohr J, Christophers E, Nordmann K, Gross WL. Mesna side effects which imitate vasculitis. Clin Invest 1992;70:698-704.
34. Fauci AS, Dale DC, Balow JE. Glucocorticoid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
35. Stuck AE, Minder CE, Frey JF. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11: 954-63.
36. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-10.
37. Le THD, Wechsler B, de Gennes C, Raguin G, Piette JC, Bletry O, et al. Aspects évolutifs et pronostiques de la granulomatose de Wegener. Rev Rhum 1989;56:583-8.